| AASLD

Home

SERIAL ENDOSCOPIC INJECTION SCLEROTHERAPY WITH N BUTYL CYANOACRYLATE GLUE VERSUS RADIOLOGICAL INTERVENTION FOR SECONDARY PROPHYLAXIS OF GASTRIC VARICEAL HEMORRHAGE IN PATIENTS WITH LIVER CIRRHOSIS (CRISP-GV): A RANDOMIZED CONTROLLED TRIAL

Read more about SERIAL ENDOSCOPIC INJECTION SCLEROTHERAPY WITH N BUTYL CYANOACRYLATE GLUE VERSUS RADIOLOGICAL INTERVENTION FOR SECONDARY PROPHYLAXIS OF GASTRIC VARICEAL HEMORRHAGE IN PATIENTS WITH LIVER CIRRHOSIS (CRISP-GV): A RANDOMIZED CONTROLLED TRIAL

<div>Background: Acute variceal bleed (AVB) from cardiofundal varices (GOV-2/IGV-1) is associated with high mortality rates in patients with liver cirrhosis. No consensus exists on the best modality to prevent rebleeding after an index episode of bleeding.

RECURR-NET, A MULTIPHASIC DEEP LEARNING MODEL, IS SUPERIOR TO MICROVASCULAR INVASION IN PREDICTING HEPATOCELLULAR CARCINOMA RECURRENCE AFTER CURATIVE SURGERY: RESULTS FROM INTERNAL VALIDATION AND EXTERNAL TESTING

Read more about RECURR-NET, A MULTIPHASIC DEEP LEARNING MODEL, IS SUPERIOR TO MICROVASCULAR INVASION IN PREDICTING HEPATOCELLULAR CARCINOMA RECURRENCE AFTER CURATIVE SURGERY: RESULTS FROM INTERNAL VALIDATION AND EXTERNAL TESTING

<div>Background: Recurrence can occur in over 70% of hepatocellular carcinoma (HCC) patients within 5 years after curative resection. While histological microvascular invasion (MVI) predicts recurrence, it is ascertained from resected specimens and cannot provide pre-operative prognostication. We developed an artificial intelligence deep learning-based model using pre-operative computed tomography (CT) for predicting HCC recurrence.

SPATIAL TRANSCRIPTOMICS IDENTIFIES IMMUNE EXPANSION OF SCAR REGIONS AND REDUCED HEPATOCYTE ZONATION IN LIVERS FROM PATIENTS WITH BILIARY ATRESIA

Read more about SPATIAL TRANSCRIPTOMICS IDENTIFIES IMMUNE EXPANSION OF SCAR REGIONS AND REDUCED HEPATOCYTE ZONATION IN LIVERS FROM PATIENTS WITH BILIARY ATRESIA

<div>Background: Multiple metabolic and inflammatory pathways have been associated with patient outcome in biliary atresia (BA), however, the spatial relevance of these pathways among BA and non-BA disease controls has not been well defined. In the present study, we overcome this gap in knowledge and define the hepatic spatial transcriptome in pediatric cholestasis.

REAL-TIME MEASUREMENTS OF BIOMARKERS FOR GRAFT ASSESSMENT AND PATIENT MONITORING

Read more about REAL-TIME MEASUREMENTS OF BIOMARKERS FOR GRAFT ASSESSMENT AND PATIENT MONITORING

<div>Background: Due to a global shortage of liver grafts, transplant surgeons increasingly resort to transplanting DCD (donated after circulatory death) organs. However, these organs are more susceptible to complications as a result of increased ischemic reperfusion injury. The worst of which is primary non-function, requiring an urgent re-transplantation. To date, there is no reliable metric to estimate the amount of reperfusion injury prior to transplantation.

IDENTIFICATION OF A REGULATORY VARIANT IN A LONG NONCODING RNA THAT INFLUENCES EXPRESSION OF EXOC3L4 AS A RISK FACTOR FOR CHOLESTATIC-MIXED DRUG-INDUCED LIVER INJURY

Read more about IDENTIFICATION OF A REGULATORY VARIANT IN A LONG NONCODING RNA THAT INFLUENCES EXPRESSION OF EXOC3L4 AS A RISK FACTOR FOR CHOLESTATIC-MIXED DRUG-INDUCED LIVER INJURY

<div>Background: Genetic factors associated with DILI susceptibility have been observed to be largely drug specific. The aim of this study was to identify novel risk factors for Cholestatic-Mixed Drug Induced Liver Injury (CM-DILI).

FOUR-YEAR OVERALL SURVIVAL UPDATE FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB PLUS DURVALUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA

Read more about FOUR-YEAR OVERALL SURVIVAL UPDATE FROM THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB PLUS DURVALUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA

<div>Background: In the primary analysis (data cut-off: 27 August 2021) of the phase 3 HIMALAYA study (NCT03298451) in unresectable hepatocellular carcinoma (uHCC), STRIDE (Single Tremelimumab Regular Interval Durvalumab) significantly improved overall survival (OS) and demonstrated a durable long-term survival benefit versus sorafenib; durvalumab monotherapy was noninferior to sorafenib (Abou-Alfa et al. NEJM Evid 2022). Here, we report an updated 4-year OS analysis of HIMALAYA.

SERUM PROTEOMICS REVEALS UNIQUE ASSOCIATION OF CCL24 WITH DISEASE-RELATED PATHWAYS AND SIGNATURES IN PRIMARY SCLEROSING CHOLANGITIS

Read more about SERUM PROTEOMICS REVEALS UNIQUE ASSOCIATION OF CCL24 WITH DISEASE-RELATED PATHWAYS AND SIGNATURES IN PRIMARY SCLEROSING CHOLANGITIS

<div>Background: Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by inflammation and fibrosis of the bile ducts. CCL24 (Eotaxin-2) is a chemokine that promotes inflammation and fibrosis and is overexpressed in the liver of patients with PSC, particularly in areas with biliary injury. Previous studies showed that blocking CCL24 interferes with core pathways that contribute to PSC pathophysiology in preclinical models.

Addition of rifaximin to broad-spectrum antibiotics has no beneficial role in critically ill cirrhosis patients with acute overt hepatic encephalopathy- A double-blind, randomized controlled trial

Read more about Addition of rifaximin to broad-spectrum antibiotics has no beneficial role in critically ill cirrhosis patients with acute overt hepatic encephalopathy- A double-blind, randomized controlled trial

<div>Background: Critically ill cirrhosis (CIC) patients admitted to the intensive care unit (ICU) are usually on broad-spectrum intravenous antibiotics due to suspected infection or as a protocol. Few reports have suggested rifaximin to be beneficial in acute overt hepatic encephalopathy (OHE). However, the role of rifaximin in patients on broad-spectrum antibiotics admitted to ICU is still unclear. Therefore, we aimed to assess the efficacy of addition of rifaximin to broad-spectrum antibiotics for CIC patients admitted to ICU for OHE.

ER-ASSOCIATED PROTEIN DEGRADATION AS A POTENTIAL ANTI-FIBROTIC TARGET IN HEPATIC STELLATE CELLS

Read more about ER-ASSOCIATED PROTEIN DEGRADATION AS A POTENTIAL ANTI-FIBROTIC TARGET IN HEPATIC STELLATE CELLS

<div>Background: Liver injury activates hepatic stellate cells (HSCs) which drive fibrosis through secreting extracellular matrix proteins. Proteins destined for secretion are cotranslationally translocated into the endoplasmic reticulum (ER), folded, and exported for secretion. Activated HSCs exhibit increased protein translation leading to ER stress, which is sensed by ER membrane proteins Activating transcription factor 6 (ATF6α), Inositol-requiring enzyme 1 (IRE1α), and Protein kinase R-like ER kinase (PERK).

POSITIVE RESULTS FROM THE ALPINE 4 STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2b TRIAL EVALUATING MULTIPLE DOSES OF THE FGF19 ANALOGUE ALDAFERMIN IN PATIENTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS

Read more about POSITIVE RESULTS FROM THE ALPINE 4 STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2b TRIAL EVALUATING MULTIPLE DOSES OF THE FGF19 ANALOGUE ALDAFERMIN IN PATIENTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS

<div>Background: Patients with cirrhosis are at increased risk of liver decompensation and HCC which can result in liver transplant or death. There is no available therapy and previous clinical trials have failed to show a benefit in patients with NASH and cirrhosis. Aldafermin, an engineered analog of the human hormone FGF19, improved liver histology in previous non-cirrhotic, phase 2 trials.

Subscribe to